Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Galmed Pharmaceuticals Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
GLMD
Nasdaq
2836
www.galmedpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals: Q3 Earnings Snapshot
- Nov 15th, 2024 1:29 pm
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
- Sep 25th, 2024 12:00 pm
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
- Sep 19th, 2024 11:00 am
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
- Apr 10th, 2024 10:30 am
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
- Apr 4th, 2024 9:06 pm
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
- Mar 15th, 2024 1:00 pm
Scroll